Evidence map›Paper›PMID 36523559›Full record

ArticleFrontiers in physiology2022

Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide's motor-stimulating and prosecretory function in the intestine.

Kimberly D Mackenzie, Mario Ortega, Yoel Kessler, Verena Ramirez Campos, Lynda J Krasenbaum, Karen Carr, Xiaoping Ning, Jennifer Stratton

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Kimberly D MackenzieTeva Pharmaceuticals, Redwood City, CA, United States.
Mario OrtegaTeva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, United States.
Yoel KesslerTeva Pharmaceutical Industries Ltd., Tel Aviv, Israel.
Verena Ramirez CamposTeva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, United States.
Lynda J KrasenbaumTeva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, United States.
Karen CarrTeva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, United States.
Xiaoping NingTeva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, United States.
Jennifer StrattonTeva Pharmaceuticals, Redwood City, CA, United States.
Teva Pharmaceuticals (United States) · USTeva Pharmaceuticals (Israel) · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Calcitonin gene-related peptide (CGRP) pathway-targeted treatments have been shown to be efficacious in the prevention of episodic and chronic migraine. Currently approved therapies include monoclonal antibodies (mAbs) that target CGRP (eptinezumab, fremanezumab, and galcanezumab) and the CGRP receptor (erenumab), and small molecule CGRP receptor antagonists (atogepant and rimegepant). While CGRP pathway-targeted treatments are generally well-tolerated, in a review article by Holzer and Holzer-Petsche published in the January 2022 issue of

Indexed as

calcitonin gene-related peptideCGRPconstipationfremanezumabmigraine

Identifiers

PMID36523559
PMCPMC9747098
OpenAlexW4310989061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.